Skip to main content

Table 3 Univariate and multivariate Cox proportional hazard analyses for the MACE according to the DAPA administration

From: Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention

  

HR

95% CI

P value

Model 1

DAPA-free

Reference

 

DAPA

0.470

0.259–0.851

0.013

Model 2

DAPA-free

Reference

 

DAPA

0.480

0.265–0.871

0.016

Model 3

DAPA-free

Reference

 

DAPA

0.440

0.233–0.833

0.012

Model 4

DAPA-free

Reference

 

DAPA

0.426

0.225–0.808

0.009

Model 5

DAPA-free

Reference

 

DAPA

0.422

0.223–0.800

0.008

Model 6

DAPA-free

Reference

 

DAPA

0.391

0.193–0.792

0.009

Model 7

DAPA-free

Reference

 

DAPA

0.388

0.192–0.785

0.008

  1. Model 1: Unadjusted
  2. Model 2: Adjusted for age, sex
  3. Model 3: Model 2 + smoking, hypertension, diabetes, cerebral infarction
  4. Model 4: Model 3 + STEMI/NSTEMI + PCI details (stenting/POBA, multivessel disease or not)
  5. Model 5: Model 4 + in-hospital AHF, in-hospital arhythmia
  6. Model 6: Model 5 + HDL-C, LDL-C, TC, TG, AIP, TyG, CPK, CK-MB, HBDH, BNP, HbA1c
  7. Model 7: Model 6 + β-block at discharge, ACEI/ARB at discharge, ARNI at discharge, MRA at discharge
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840